RAPID TEST SYSTEM FOR MYCOBACTERIAL SUSCEPTIBILITY

耐多药结核病的控制受到严重阻碍。 由于缺乏快速的抗菌药敏感性检测方法和 分支杆菌感染的诊断。拟议的研究提供了一种 一种基于One的快速抗生素敏感性检测方法 细胞系统公司的专利微滴技术。单株分枝杆菌 微克隆将被封装并在一个非常小的克隆中生长 由凝胶微滴(GMD)定义的区域。通过以下方式自动分析GMD 克隆生长和荧光染色后的流式细胞术 生物体构成了这个化验系统的基础。易感性 使用GMD在5天内检测到分枝杆菌对抗生素的耐药性- 克隆生长法，从而论证了该方法的基本可行性 接近。第一阶段研究的目标是开发定量的 分枝杆菌生长和抗药性的评价方法 抗菌剂。这些实验将形成一个基础 商业上可行的快速分枝杆菌检测系统，利用 在微尺度上的常规方法。结核病的重新出现成为 美国的一个公共卫生问题表明，迫切需要 这样一种测试系统。

The control of multidrug resistant tuberculosis has been severely hampered by the lack of rapid methods for antimicrobial susceptibility testing and diagnosis of mycobacterial infection. The research proposed provides a novel approach to rapid antibiotic susceptibility testing, based on One Cell Systems' proprietary microdrop technology. Individual mycobacterial microcolonies will be encapsulated and grown within a very small cloning region defined by a gel microdrop (GMD). Automated analysis of GMDs by flow cytometry following clonal growth and fluorescent staining of the organisms forms the basis of this assay system. Susceptibility of mycobacteria to antibiotics has been detected in 5 days using the GMD- clonal growth method, thus demonstrating the basic feasibility of this approach. The goals of the Phase I research are to develop quantitative methods for evaluation of mycobacterial growth and resistance to antimicrobial agents. These experiments will form the basis for a commercially viable, rapid mycobacterial assay system, utilizing conventional methods at a microscale. The re-emergence of tuberculosis as a public health problem in the United States points to the urgent need for such a testing system.